ALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three years
Allergy company ALK will receive crucial trial data from partner Windgap which is working on a next-generation adrenaline pen which ALK has the rights to. Meanwhile, ALK is developing its own adrenaline pen based on experiences with Jext. The firm is confident it will be submitting a registration application to the US FDA before 2024.
BY ALBERT RØNNING_ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
ALK's allergy specialists want more than a dominant position in the US market for tablet treatments for patients with allergies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
